

해외 바이오의약품 임상 현황 ('24년 3월 2주)

한국바이오의약품협회, 2024.03.19.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.03.11.~2024.03.17.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 12건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05813327	Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma	Drug: ADI PEG20 Drug: Ifosfamide Radiation: Radiotherapy Drug: Mesna	Washington University School of Medicine Polaris Group	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05813327
NCT06305910	CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults	Drug: Treatment with CD200AR-L	OX2 Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT06305910
NCT06266338	Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)	Drug: Pembrolizumab Drug: Lenvatinib	University of Texas Southwestern Medical Center Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06266338
NCT06265285	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Other: Home Health Encounter Biological: Nivolumab Procedure: Patient Monitoring Other: Questionnaire Administration	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06265285
NCT06130540	Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR	Drug: Secukinumab	Novartis Pharmaceuticals Novartis	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT06130540
NCT05887167	Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies	Biological: autologous hematopoietic stem cells added to planned CAR T	Joshua Sasine, MD, PhD Cedars-Sinai Medical Center	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05887167
NCT05618925	Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma	Drug: N803 Biological: CD19t-haNK suspension Drug: Cyclophosphamide Drug: Fludarabine Drug: Rituximab	ImmunityBio, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05618925
NCT05546723	LMY-920 for Treatment of Relapsed or Refractory Myeloma	Biological: Autologous CAR-T cell therapy expressing the BAFF-ligand.	Luminary Therapeutics The Cleveland Clinic Case Western Reserve University	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05546723
NCT05923073	A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Drug: Guselkumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05923073
NCT06238635	Dostarlimab and Cobolimab in Advanced Cervical Cancer	Drug: Dostarlimab Drug: Cobolimab	Meghan Shea GlaxoSmithKline Beth Israel Deaconess Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06238635
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT06232707
NCT05509777	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05509777

해외 바이오의약품 임상 현황 ('24년 3월 2주)

한국바이오의약품협회, 2024.03.19.

○ 영국 2건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT05509777	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05509777

○ 프랑스 2건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707
NCT05509777	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05509777

○ 독일 1건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707

○ 중국 7건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06307925	A Phase I Open-label, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors	Drug: HC010	HC Biopharma Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06307925
NCT06307054	CLL-1 CAR-NK Cells for Relapsed/Refractory AML	Drug: anti-CLL-1 CAR NK cells	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06307054
NCT06293690	Toripalimab Combined With SBRT for NSCLC	Drug: Toripalimab	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06293690
NCT06285279	FKC288 in Participants With Autoimmune Kidney Diseases	Drug: FKC288	Nanjing University School of Medicine	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06285279
NCT05116462	Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer	Drug: Pemetrexed Drug: Carboplatin Drug: Paclitaxel Drug: Sintilimab Drug: Cisplatin Drug: Nab paclitaxel Drug: Placebo	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05116462
NCT06271837	A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors	Drug: Trastuzumab deruxtecan	AstraZeneca Daiichi Sankyo Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06271837
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06232707

해외 바이오의약품 임상 현황 ('24년 3월 2주)

한국바이오의약품협회, 2024.03.19.

○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05923073	A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease	Drug: Guselkumab Drug: Placebo	Janssen Research & Development, LLC	Phase 3	https://clinicaltrials.gov/study/NCT05923073
NCT06232707	A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Drug: Alnuctamab Drug: Pomalidomide Drug: Daratumumab Drug: Elotuzumab Drug: Carfilzomib Drug: Dexamethasone	Celgene	Phase 3	https://clinicaltrials.gov/study/NCT06232707
NCT05509777	A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Drug: Mirikizumab	Eli Lilly and Company	Phase 3	https://clinicaltrials.gov/study/NCT05509777